Navigation Links
Shire plc: Third Quarter 2010 Results Date Notification - October 29, 2010
Date:10/18/2010

Shire plc: Third Quarter 2010 Results Date Notification - October 29, 2010 -- DUBLIN, October 18, 2010 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, New Products & Services Click to view news release full screen  

Shire plc: Third Quarter 2010 Results Date Notification - October 29, 2010

 

DUBLIN, October 18, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, will announce third quarter 2010 earnings on Friday 29 October, 2010.

Results press release will be 12:00 BST / 07:00 EDT issued at: Investor conference call 14:00 BST / 09:00 EDT time:

Live conference call for investors:

Angus Russell, Chief Executive Officer and Graham Hetherington, Chief Financial Officer will host the investor and analyst conference call at 14:00 BST/9:00 EDT.

The details of the conference call are as follows: UK dial in: 0844-335-0351 US dial in: 1-866-8048688 or 1-718-3541175 International dial +44-844-335-0351 in: Password/Conf ID: 921 510 Live Webcast: http://www.shire.com/shireplc/en/investors

Replay:

A replay of the presentation will be available for two weeks by phone and by webcast for one year. Details can be found on our Investor Relations website http://www.shire.com/shireplc/en/investors.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

For further information please contact: Investor Relations Souheil Salah (Rest of the World) +44-1256-894-160 Ricki Greenwood (North America) +1-484-595-8517
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Atrium Recognized by New Hampshire Bio/Medical Council
2. Shire Update on ProAmatine(R) (midodrine HCl)
3. Shire Announces Support for Inflammatory Bowel Disease (IBD) Fellowships at Leading Medical Institutions Nationwide
4. Pentasa(R) - Shire Receives Ruling From FDA on Citizens Petition
5. Shire Purchases Strategic Site in Massachusetts
6. Shire Receives LIALDA(R) Paragraph IV Notice Letter From Zydus Pharmaceuticals
7. Area Residents Can Give a Little, Help A Lot at Shires BIG GIVE
8. Shire Receives INTUNIV(TM) Paragraph IV Notice Letter From Anchen
9. Excellent Results in a Transformational Year for Shire; Core Product Sales up 25%
10. Shire Presents Positive Efficacy and Safety Data for velaglucerase alfa in Treatment of Naive Patients With Type 1 Gaucher Disease
11. Shire Submits Biologics License Application (BLA) for REPLAGAL(R) With the U.S. Food and Drug Administration (FDA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... February 9, 2016 ... heute den Abschluss eines Kooperationsvertrags mit 10x ... Lösungen in den Bereichen Next-Generation-Sequencing (NGS), Single-Cell-Biology ... ; Frankfurt Prime Standard: QIA) gab heute ... für die Entwicklung und Förderung umfassender Lösungen ...
(Date:2/9/2016)... ORLANDO, Florida , February 9, 2016 /PRNewswire/ ... QIA) today announced a collaboration with 10x Genomics ... sequencing (NGS), single-cell biology and bioinformatics. --> ... announced a collaboration with 10x Genomics to develop ... single-cell biology and bioinformatics. --> QIAGEN ...
(Date:2/9/2016)... -- Mast Therapeutics, Inc. (NYSE MKT: MSTX), a ... and heart failure, today announced that it intends to offer ... in an underwritten public offering.  The offering is subject to ... as to whether or when the offering may be completed, ... offering.   --> --> ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... February 09, 2016 , ... METTLER TOLEDO has ... personnel have a basic understanding of the techniques they use so they can ... help them reduce waste and rework to create a leaner overall lab experience. ...
(Date:2/9/2016)... ... ... i2i Systems, an early innovator and developer of population health management technology, ... report, Population Health Management 2015: How Far Can Your Vendor Take You? , ... The latest KLAS Report, leveraging over 200 user interviews, shines a light on ...
(Date:2/8/2016)... ... 08, 2016 , ... Brenntag Specialties, Inc.(BSI) , is ... & Beverage and Dietary Supplement market segments across the western ... geographies east of the Rocky Mountains since 2012. Consistent performance in business ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... L top-load case packer for pouches, bags, and flow wrapped products at WestPack ... co-packers and specialty product manufacturers step up to semi-automatic or fully-automatic case packing ...
(Date:2/8/2016)... ... February 08, 2016 , ... Local insurance agency ... Venice, FL area, has initiated a fundraiser for a two year old little ... days after Christmas. To support this beautiful child who is facing life’s journey ...
Breaking Medicine News(10 mins):